Regeneron Pharmaceuticals

Yahoo Finance • 16 hours ago

Jim Cramer Says He “Should Have Been Recommending Regeneron”

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the stocks Jim Cramer answered questions about. Answering a caller’s query about the stock, Cramer stated: “I should have been recommending Regeneron. That Len Schleifer pulled the r... Full story

Yahoo Finance • 22 hours ago

Notable healthcare headlines for the week: Abbott, Medtronic, Merck and J&J in focus

Wall Street staged a rebound on Friday, closing the session in positive territory after a turbulent, tech-driven downturn rattled the Nasdaq Composite just a day earlier. Friday's market boost was supported by reports that the Trump admin... Full story

Yahoo Finance • 3 days ago

Mettler-Toledo, Agilent, Waters Corporation, Merck, and Regeneron Shares Skyrocket, What You Need To Know

What Happened? A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a fur... Full story

Yahoo Finance • 4 days ago

Stocks to Watch Thursday Recap: Walmart, Nvidia, Cracker Barrel, Regeneron

↗️ Walmart (WMT): The biggest U.S. retailer and private-sector employer posted solid quarterly results and raised its outlook. Shares closed up nearly 6.5%. ↘️Nvidia (NVDA): The chip maker reported record sales and issued strong guidance,... Full story

Yahoo Finance • 5 days ago

Regeneron gets FDA nod for Eylea in macular edema treatment

[Digital Eye Wave Lines Stock Background] Sharamand/iStock via Getty Images * Regeneron Pharmaceuticals (REGN [https://seekingalpha.com/symbol/REGN]) has received approval from the U.S. FDA for Eylea HD (aflibercept) Injection 8 mg for... Full story

Yahoo Finance • 5 days ago

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing flexibility for more personalized patie... Full story

Yahoo Finance • 5 days ago

REGN Factor-Based Stock Analysis - Benjamin Graham

Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep valu... Full story

Yahoo Finance • 5 days ago

Regeneron gets EU nod for expanded approval of Libtayo

[Digital Eye Wave Lines Stock Background] Sharamand/iStock via Getty Images Regeneron Pharmaceuticals (REGN [https://seekingalpha.com/symbol/REGN]) has received approval from the European Commission for Libtayo (cemiplimab), to be used as... Full story

Yahoo Finance • 11 days ago

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this setting Additional oral presentation spotli... Full story

Yahoo Finance • 14 days ago

Analysts Anticipate EPS To Hit $79

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 16 days ago

Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%

Merck said Saturday its new pill — a potential rival to Regeneron and Amgen — lowered stubbornly high cholesterol by almost 60%. Continue Reading View Comments... Full story

Yahoo Finance • 16 days ago

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results consistent with prospective design of thes... Full story

Yahoo Finance • 17 days ago

Benjamin Graham Detailed Fundamental Analysis - REGN

Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep valu... Full story

Yahoo Finance • 17 days ago

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase 3 data to be presented at ACAAI demon... Full story

Yahoo Finance • 17 days ago

Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique...

ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique ; la demande supplémentaire... Full story

Yahoo Finance • 18 days ago

High Concentration mAb Products Market Advancing Precision Biopharmaceutical Therapeutics – Towards Healthcare

Ottawa, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Drug products formulated with high concentrations of monoclonal antibodies (mAbs) represent a distinct and advanced class of biopharmaceuticals. These therapies are typically administered subcuta... Full story

Yahoo Finance • 22 days ago

Notable healthcare headlines for the week: UNH, Eli Lilly and Merck in focus

Wall Street rallied higher as investors digested upbeat earnings from big tech companies during the week. The Nasdaq gained 2.2%, the S&P 500 moved up by 0.7%, and the Dow added 0.7% this week. However, the S&P 500 Health Care Index Sect... Full story

Yahoo Finance • 26 days ago

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results

MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and rece... Full story

Yahoo Finance • 26 days ago

Regeneron Adds Fuel to Hot Healthcare Trade. Which Stocks Could Follow it Higher?

The 7% rally over the past month has been outdone only by technology stocks. The last two months alone have seen Metsera Avidity Biosciences Merus, 89bio and Akera Therapeutics all bought out. The stock, which many considered dead money at... Full story

Yahoo Finance • 27 days ago

Sector Update: Health Care Stocks Retreat Tuesday Afternoon

Health care stocks declined Tuesday afternoon, with the NYSE Health Care Index shedding 0.5% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story